Divozilimab

Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20) . Divozilimab can be used for multiple sclerosis research[1].

Product Specifications

CAS Number

[2254061-60-2]

Product Name Alternative

BCD-132

UNSPSC

12352203

Target

CD20

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/divozilimab.html

Purity

99.63

Solubility

10 mM in DMSO

Smiles

[Divozilimab]

Molecular Weight

(145.26 kDa)

References & Citations

[1]O V Boyko, et al. Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132) : pharmacokinetics, pharmacodynamics and safety. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119 (10. Vyp. 2) :87-95.|[2]Boyko AN, et al. Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123 (4) :37-47. Russian.